Clinical Benefit of Antisense Therapy in a Phase III Trial in Patients With CLL

Cancer Biology and Therapy - United States
doi 10.4161/cbt.6.3.4165
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Informa UK Limited


Related search